Skip to main content
SpringerLink
Log in

Vorapaxar

  • Adis R&D Profile
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Merck. New Merck Begins Operations. www.merck.com, 05 Nov 2009.

  2. Schering-Plough Corporation. Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348). www.schering-plough.com, 18 Apr 2007.

  3. Merck and Co. Merck Announces Completion of Patient Enrollment in Phase III TRA-2°P-TIMI 50 Trial of SCH 530348, a Novel, Oral Antiplatelet PAR-1 Inhibitor. www.merck.com, 14 Nov 2009.

  4. Merck and Co. Inc. Merck Announces Second-Quarter 2010 Financial Results. www.merck.com, 30 Jul 2010.

  5. Schering-Plough Corporation. Schering-Plough’s Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study. www.schering-plough.com, 12 Mar 2009.

  6. Schering-Plough Corporation. Schering-Plough’s Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial. www.schering-plough.com, 24 Mar 2007.

  7. Schering-Plough Corporation. Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study — Part B. www.schering-plough.com, 22 Nov 2007.

  8. Schering-Plough Corporation. Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study — Part A. www.schering-plough.com, 22 Oct 2007.

  9. Scherin Plough Corporation. Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study — Part C. www.schering-plough.com, 22 Nov 2007.

  10. Schering-Plough Corporation. FDA Grants Fast Track Designation to Schering-Plough for its Thrombin Receptor Antagonist SCH 530348. www.schering-plough.com, 20 Apr 2006.

  11. Schering-Plough Corporation. Schering-Plough Reports Financial Results for First Quarter of 2006. www.schering-plough.com, 20 Apr 2006.

  12. Schering-Plough Corporation. Schering-Plough Highlights R&D Pipeline and Product Portfolio at Analysts and Portfolio Managers Meeting. www.schering-plough.com, 01 Nov 2005.

  13. Reyderman L, Kosoglou T, Tseng J, et al. The effect of food and antacid on pharmacokinetics of SCH 530348 in healthy subjects. 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. S21 abstr. PI-42, 18 Mar 2009. Available from URL: http://www.nature.com.

  14. Kosoglou T, Reyderman L, Fales RR, et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor antagonist SCH 530348. Circulation 2005 Oct 25; 112 (Suppl.): 32, No. 17.

    Google Scholar 

  15. Kosoglou T, Reyderman L, Kasserra C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clinical Pharmacology and Therapeutics 2008 Mar; 83 (Suppl. 1): 55.

    Google Scholar 

  16. Goto S, Yamaguchi T, Ikeda Y, et al. Phase II trial of the novel antipaltelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes. ESC Congress 2008: Annual Congress of the European Society of Cardiology. abstr. P4767, 30 Aug 2008. Available from URL: http://www.escardio.org.

  17. Moliterno DJ, Becker RC, Jennings LK, et al. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist (SCH 530348) in percutaneous coronary intervention. 56th Annual Scientific Session of the American College of Cardiology: Late Breakers i2 Summit. (plus oral presentation), 24 Mar 2007.

  18. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 14 Mar; 373: 919–28, No. 9667.

    Article  PubMed  CAS  Google Scholar 

  19. Kosoglou T, Tiessen R, Van Vliet AA, et al. Safety and tolerability of SCH 530348, a novel antiplatelet agent, after single and multiple oral dosing in healthy subjects. ESC Congress 2008: Annual Congress of the European Society of Cardiology. abstr. P1340, 30 Aug 2008. Available from URL: http://www. escardio.org. Summary in 2 parts (Part A).

  20. Reyderman L, Kosoglou T, Kasserra C, et al. Lack of ethnic differences in the pharmacodynamics and pharmacokinetics of SCH 530348 a novel oral antiplatelet agent in Japanese and caucasion subjects. 110 th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. S21 abstr. PI-41, 18 Mar 2009. Available from URL: http://www.nature.com.

  21. Chintala M, Ahn H-S, Foster C, et al. Pharmacologica profile of SCH 53048, a novel oral antiplatelet agent selective for the protease-activated receptor-1.81st Annual Scientific Sessions of the American Heart Association. 374 abstr. 1710, 8 Nov 2008. Available from URL: http://scientificsessions. americanheart.org.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vorapaxar. Am J Cardiovasc Drugs 10, 413–418 (2010). https://doi.org/10.2165/11533530-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533530-000000000-00000

Search

Navigation